InvestorsHub Logo
Followers 829
Posts 119629
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Saturday, 11/19/2022 12:22:19 PM

Saturday, November 19, 2022 12:22:19 PM

Post# of 83
Tzield is a major breakthrough—maybe (NYT):

https://www.nytimes.com/2022/11/18/health/fda-type-1-diabetes-delay.html

There’s a dilemma vis-à-vis the right time to start therapy. If started too early—i.e. when the patient has detectable autoimmune antibodies but does not yet have damage to the pancreas—Tzield may not work. OTOH, if therapy is started too late—when damage to the pancreas has already occurred—the clinical benefit is reduced to some degree.

A further problem is that screening for autoimmune antibodies capable of causing T1D is rarely done unless a patient has close relatives already diagnosed with T1D.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”